Clinical Trial Update: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of NIS793 in combination with FOLFIRINOX for pancreatic cancer was terminated, with results posted on 2024-07-16.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• NIS793 (NIS-793)

Snippet

Sponsor: Kimberly Perez, MD | Conditions: Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-07-16